Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUR-928 in Alcoholic Hepatitis
NCT03432260Phase 2Completed
- Sponsor
- DURECT Corporation
- Start
- Apr 2018
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of larsucosterol in alcoholic hepatitis (AH) (6 arms), sponsored by DURECT Corporation. Primary endpoints: Lille Model for Alcoholic Hepatitis Score at Day 7, Model for End Stage Liver Disease Score at Day 28 and 1 more. Started Apr 2018; status: completed.
02
Drugs
larsucosterol
03
Conditions
alcoholic hepatitis (AH)
Beyond the preview
Go deeper on NCT03432260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03432260.